埃塞俄比亚阿姆哈拉州 SAFE 策略实施五年后眼部沙眼衣原体基因组学研究
研究对埃塞俄比亚阿姆哈拉州 99 份眼部沙眼衣原体(Ct)样本进行测序,分析 Ct 基因组变异在持续传播中的作用。结果显示序列在全基因组和组织嗜性相关基因上符合眼部 Ct 特征,未发现大环内酯类耐药证据;ompA 基因多态性与村层面沙眼性炎症-滤泡患病率相关,区层面 ompA 多样性较高与 Ct 感染患病率增加相关。
要点
- 未发现 Ct 基因组变异导致治疗后持续传播的证据。
- 未检测到大环内酯类耐药,支持阿奇霉素不驱动耐药。
- ompA 多样性较高区域 Ct 感染患病率增加,需纵向研究。
核心结论
- 未发现 Ct 基因组变异在治疗后持续传播中起作用的证据,且无大环内酯类耐药证据。
- ompA 多样性较高地区 Ct 感染增加,需纵向研究其对治疗成功和宿主免疫的影响。
研究设计与样本
- 利用 Abbott m2000 Ct 诊断检测的残余材料,对埃塞俄比亚阿姆哈拉州 99 份眼部 Ct 样本进行测序。
- 调查 Ct 基因组变异在持续传播中的作用。
主要发现
- 序列在全基因组水平和组织嗜性相关基因上符合眼部 Ct 的典型特征。
- 该人群中无大环内酯类耐药证据。
- ompA 基因周围多态性与村层面沙眼性炎症-滤泡患病率相关。
- 区层面 ompA 多样性较高与 Ct 感染患病率增加相关。
临床怎么用
- 提示阿奇霉素大规模治疗未驱动 Ct 大环内酯类耐药,支持继续使用。
- ompA 多样性较高地区需关注 Ct 感染风险,但治疗成功影响需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To eliminate trachoma as a public health problem, the World Health Organization recommends the SAFE (surgery, antibiotics, facial cleanliness, and environmental improvement) strategy. As part of the SAFE strategy in the Amhara Region, Ethiopia, the Trachoma Control Program distributed >124 million doses of antibiotics between 2007 and 2015. Despite this, trachoma remained hyperendemic in many districts and a considerable level of Chlamydia trachomatis (Ct) infection was evident. METHODS: We utilized residual material from Abbott m2000 Ct diagnostic tests to sequence 99 ocular Ct samples from Amhara and investigated the role of Ct genomic variation in continued transmission of Ct. RESULTS: Sequences were typical of ocular Ct at the whole-genome level and in tissue tropism-associated genes. There was no evidence of macrolide resistance in this population. Polymorphism around the ompA gene was associated with village-level trachomatous inflammation-follicular prevalence. Greater ompA diversity at the district level was associated with increased Ct infection prevalence. CONCLUSIONS: We found no evidence for Ct genomic variation contributing to continued transmission of Ct after treatment, adding to evidence that azithromycin does not drive acquisition of macrolide resistance in Ct. Increased Ct infection in areas with more ompA variants requires longitudinal investigation to understand what impact this may have on treatment success and host immunity.
引用
- Pickering H, Chernet A, Sata E, et al. Genomics of Ocular Chlamydia trachomatis After 5 Years of SAFE Interventions for Trachoma in Amhara, Ethiopia. J Infect Dis. 2022. PMID: 33034349. doi:10.1093/infdis/jiaa615
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。